Esperion Therapeutics, Inc. (ESPR) Research
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
Market snapshot
- Symbol
- ESPR
- Price
- $3.15
- Day change
- -0.63%
- Market cap
- $654.9M
- P/E ratio
- -106.66x
- 52-week range
- 0.95-4.18
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $3.19
Recent news
- Archimed to take Esperion Therapeutics private in $1.1 billion deal
Investment firm Archimed will take Esperion Therapeutics private for up to $1.1 billion, the companies said on Friday, sending the drugmaker's shares up over 55% in premarket trading.
Peer companies
Recent insider activity
- Looker Benjamin — S-Sale (11824 shares) on 2026-06-17
- Koenig Sheldon L. — S-Sale (53588 shares) on 2026-06-17
- Halladay Benjamin — S-Sale (10773 shares) on 2026-06-17
- THOMPSON JOHN CRAIG — A-Award (79873 shares) on 2026-05-28
- Shepard Jay — A-Award (79873 shares) on 2026-05-28
Open Esperion Therapeutics, Inc. (ESPR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.